Description: Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. It develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism, nash, and diabetes. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden.
Home Page: www.sprintbioscience.com
Novum
Huddinge,
141 57
Sweden
Phone:
46 84 11 44 55
Officers
| Name | Title |
|---|---|
| Mr. Johan Emilsson | Chief Executive Officer |
| Prof. Pär Nordlund | Founder |
| Dr. Martin Andersson | Co-Founder & Chief Scientific Officer |
| Dr. Kenth Hallberg | Founder & Director of Structural Chemistry |
| Mr. Mathias Skalmstad | Chief Financial Officer |
| Ms. Anne-Marie Wenthzel | Chief Business Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.4033 |
| Price-to-Sales TTM: | 0.1641 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 36 |